inspirator schreef op 26 augustus 2015 23:57:
Bladder Cancer
Consistent with our focus in the urology market, MDxHealth is accelerating the development of our ConfirmMDx for Bladder Cancer test. The test is designed to rule-out bladder cancer in patients diagnosed with hematuria, who are traditionally followed with cytology and cystoscopy. Although cytology and cystoscopy are the standard of care, these methodologies are prone to miss small papillary bladder tumors, satellite lesions as well as carcinoma in situ. The ConfirmMDx for Bladder Cancer test is a urine-based test designed to help rule out the presence of cancer, sparing many patients invasive cystoscopy procedures, and aiding in the identification of high-risk patients requiring further examination.
The use of epigenetic markers for bladder cancer detection to improve on current diagnostic procedures, like cystoscopy, has been well studied and evaluated in more than 300 scientific publications. The Company has filed for patent protection on TWIST1 and NID2, two of the most intensively studied and widely reported epigenetic biomarkers associated with bladder cancer diagnosis. We are currently working on the completion of a bladder cancer verification and validation study and expect to publish the data in the course of 2015.1
Additionally, in the future we intend to validate our RecurMDx for Bladder Cancer test to address the need for improved monitoring of diagnosed bladder cancer patients. More than 60% of early stage bladder cancer patients will have a recurrence following treatment and it is estimated that more than 500,000 Americans are currently under surveillance for recurrent bladder cancer.2